VOR VS GRAY Stock Comparison

Performance

VOR
10/100

VOR returned -61.10% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

GRAY
10/100

GRAY returned -72.53% in the last 12 months. Based on the other stocks in it's sector with an average return of -31.04%, it's performance is below average giving it a grade of 10 of 100.

Technicals

VOR
10/100

VOR receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.

GRAY
14/100

GRAY receieves a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.

Earnings

VOR
10/100

VOR has missed earnings 6 times in the last 20 quarters.

GRAY
10/100

GRAY has missed earnings 7 times in the last 20 quarters.

Profit

VOR
10/100

Out of the last 16 quarters, VOR has had 0 profitable quarters and has increased their profits year over year on 0 of them.

GRAY
10/100

Out of the last 7 quarters, GRAY has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

VOR
43/100

VOR has had a lower than average amount of volatility over the last 12 months giving it a score of 42 of 100.

GRAY
54/100

GRAY has had a higher than average amount of volatility over the last 12 months giving it a grade of 54 of 100.

Forecast

VOR

"Forecast" not found for VOR

GRAY
88/100

4 analysts offer 12-month price forecasts for GRAY. Together, they have an average target of 392, the most optimistic forecast put GRAY at 392 within 12-months and the most pessimistic has GRAY at 392.

All score calculations are broken down here to help you make more informed investing decisions

Vor Biopharma Inc. Common Stock Summary

Nasdaq / VOR

Healthcare

Biotechnology

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Graybug Vision, Inc. Summary

Nasdaq / GRAY

Healthcare

Biotechnology

Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.

Power up your portfolio